Effects of MitoQ on mobility and cognitive performance in frail older adults

The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults

This study is testing if a supplement called MitoQ can help frail older adults aged 65-80 improve their walking and thinking abilities compared to a placebo.

Quick facts

• Phase: PHASE2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Ages: 65 Years to 80 Years
• Sex: All
• Sponsor: UConn Health (other)
• Drugs / interventions: chemotherapy
• Locations: 1 site (Farmington, Connecticut)
• Trial ID: NCT06027554 on ClinicalTrials.gov

What this trial studies

This clinical trial investigates the impact of MitoQ supplementation on vascular function, oxidative stress, and both physical and cognitive performance in frail older adults aged 65-80. The study aims to compare these factors between participants with slow gait speed and mild cognitive impairment. By targeting the shared mechanisms of aging and chronic conditions, the trial seeks to enhance mobility and cognitive capabilities in this vulnerable population. Participants will receive either MitoQ or a placebo to assess the potential benefits of this intervention.

Who should consider this trial

Good fit: Ideal candidates are men and women aged 65-80 with slow gait speed and/or mild cognitive impairment who are in good cardiovascular health.

Not a fit: Patients with recent infections, severe autoimmune diseases, or those on blood thinners may not benefit from this study.

Why it matters

Potential benefit: If successful, this trial could improve mobility and cognitive function in frail older adults, potentially enhancing their quality of life and independence.

How similar studies have performed: While some studies have explored interventions for frailty and cognitive decline, the specific approach of using MitoQ in this context is relatively novel.

Eligibility criteria

Inclusion Criteria:

* men and women aged 65-80 with a slow gait speed (0.4m/s based on a 4m walk) and/or mild cognitive impairment.
* good cardiovascular health (not taking any blood pressure/flow/metabolism altering medications)

Exclusion Criteria:

* A vaccination in past two weeks
* Recent acute infection three weeks prior to enrollment
* Known immunodeficiency (including HIV infection, primary immunodeficiency, any history of chemotherapy or radiotherapy
* Use of medicines during past 6 months known to alter immune response such as high- dose corticosteroids
* Severe autoimmune disease requiring biological therapy
* Major severe illness and/or Hospitalization in past 3 months
* On warfarin or other medications that are considered a blood thinner
* Recent fall or other conditions that will impair ability to complete and/or interpret mobility performance test
* Known bleeding disorder
* Any conditions that would impair the function to perform grip strength test
* include advanced neurological disease, severe co-morbid disease, terminal illness with reduced life expectancy, severe disability, unintentional weight loss in last 12 months and participation in another study.
* Diabetes patients requiring insulin (For reducing the risk that participants will have hypoglycemic episodes when fasting for study visits)
* Baseline ECG QTc \>450 ms in men and QTc \>460 ms in women
* Prior diagnosis of ventricular arrhythmia (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes)

Where this trial is running

Farmington, Connecticut

• UConn Health — Farmington, Connecticut, United States (RECRUITING)

Study contacts

• Principal investigator: Oh Sung Kwon, PhD — University of Connecticut
• Study coordinator: Oh Sung Kwon, PhD

Conditions: Frailty, Mild Cognitive Impairment, Aging